CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms CARMELINA
- Sponsors Boehringer Ingelheim
- 09 Feb 2018 Status changed from active, no longer recruiting to completed.
- 24 Jan 2018 The study has been completed in Czech Republic.
- 22 Jan 2018 Planned End Date changed from 11 Dec 2017 to 22 Jan 2018.